aripiprazole

• compliance with study protocol

  increases, n = 2275

  It also produced better compliance with study protocol (n = 2275, 8 RCTs, RR 0.74 CI 0.59 to 0.93)

  PMID:21833956 · one of two readings recorded this

• leaving the study early

  decreases, n = 2585

  Fewer people left the aripiprazole group compared with those in the placebo group (n = 2585, 9 RCTs, RR 0.73 CI 0.60 to 0.87)

  PMID:21833956 · one of two readings recorded this

• raised prolactin

  decreases, n = 305

  Aripiprazole may decrease prolactin levels below those expected from placebo (n = 305, 2 RCT, RR 0.21 CI 0.11 to 0.37)

  PMID:21833956 · one of two readings recorded this

• relapse in the short and medium term, aripiprazole versus placebo in people with schizophrenia or schizophrenia-like psychosis, pooled risk ratio

  decreases, short term RR 0.59 CI 0.45 to 0.77; medium term RR 0.66 CI 0.53 to 0.81 (n = 310, 1 RCT), n = 310

  Not recorded as a finding: this platform holds no node for the endpoint

  Compared with placebo, aripiprazole significantly decreased relapse in both the short (n = 310, 1 RCT, RR 0.59 CI 0.45 to 0.77) and medium term (n = 310, 1 RCT, RR 0.66 CI 0.53 to 0.81).

  PMID:21833956 · one of two readings recorded this

• relapse in the short and medium term, aripiprazole vs placebo in schizophrenia, risk ratio

  decreases

  Not recorded as a finding: this platform holds no node for the endpoint

  Compared with placebo, aripiprazole significantly decreased relapse in both the short (n = 310, 1 RCT, RR 0.59 CI 0.45 to 0.77) and medium term (n = 310, 1 RCT, RR 0.66 CI 0.53 to 0.81).

  PMID:21833956 · one of two readings recorded this

• relapse

  decreases, n = 310

  short (n = 310, 1 RCT, RR 0.59 CI 0.45 to 0.77)

  PMID:21833956 · one of two readings recorded this

• discontinuation, pooled

  no effect, p = 0.99

  (risk difference (Mantel-Haenszel, fixed) −0.00 (95% confidence interval −0.06 to 0.06); I2 = 0%, P = 0.99)

  PMID:23936389 · one of two readings recorded this

• discontinuation, pooled

  no effect, p = 0.46

  (risk difference (Mantel-Haenszel, fixed) −0.02 (95% confidence interval −0.09 to 0.04); I2 = 0%, P = 0.46)

  PMID:23936389 · one of two readings recorded this

• extrapyramidal symptoms, dry mouth and fatigue (pooled adverse events)

  no effect

  Meta-analysis of extrapyramidal symptoms, dry mouth, and fatigue showed no significant differences between the two groups

  PMID:23936389 · one of two readings recorded this

• galactorrhea resolved

  decreases, n = 2

  1 of 2 patients (50%) no longer complained symptoms of galactorrhea in adjunctive aripiprazole group

  PMID:23936389 · one of two readings recorded this

• galactorrhea resolved

  decreases, n = 16

  In another study, 27 of 28 (96.43%) patients regained menstruation, and 16 of 16 (100%) patients no longer complained symptom of galactorrhea in aripiprazole group

  PMID:23936389 · one of two readings recorded this

• improvement in psychiatric symptoms (PANSS or BPRS total score change)

  no effect, p = 0.17

  (mean difference (Inverse-Variance, fixed) −0.46 (95% confidence interval −1.13 to 0.20); I2 = 0%, P = 0.17)

  PMID:23936389 · one of two readings recorded this

• insomnia, headache, sedation and psychiatric disorder (pooled adverse events)

  no effect

  Meta-analysis of insomnia, headache, sedation, and psychiatric disorder showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization, pooled

  increases, p = 0.00001

  (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I2 = 43%, P<0.00001)

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization, pooled

  increases, p = 0.00001

  (risk difference (Mantel-Haenszel, random) 0.74 (95% confidence interval 0.62 to 0.87); I2 = 59%, P<0.00001)

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization (proportion of patients with serum prolactin below the study's normal cut-off), adjunctive aripiprazole versus adjunctive placebo in antipsychotic-induced hyperprolactinemia

  increases, risk difference 0.76 (95% CI 0.67 to 0.85); I2 = 43%, P<0.00001

  Not recorded as a finding: this platform holds no node for the endpoint

  Meta-analysis of the prolactin level normalization showed adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I2 = 43%, P<0.00001).

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization rate (serum prolactin below the study-defined normal threshold), adjunctive aripiprazole vs adjunctive placebo in antipsychotic-induced hyperprolactinemia

  increases, risk difference 0.76, 95% CI 0.67 to 0.85

  Not recorded as a finding: this platform holds no node for the endpoint

  Meta-analysis of the prolactin level normalization showed adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I2 = 43%, P<0.00001).

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization rate

  increases, n = 72

  Chen 2009 | Placebo-controlled,double-blind | Male | 8 | 72 | Risperidone | 5 | Aripiprazole: 67.6%Placebo: 6.5% | _

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization rate

  increases, n = 130

  Ji 2008 | Placebo-controlled,single-blind | Female | 6 | 130 | Risperidone | 5 | Aripiprazole: 82.0%Placebo: 4.0% | _

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization rate

  increases, n = 322

  Kane 2009 | Placebo-controlled,double-blind | Either gender | 16 | 322 | Risperidone Quetiapine | 5–15 | Aripiprazole: 19.5%Placebo: 9.1% | _

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization rate

  increases, n = 54

  Shim 2007 | Placebo-controlled,double-blind | Either gender | 8 | 54 | Haloperidol | 15–30 | Aripiprazole: 88.5%Placebo: 3.6% | 7/11 patients regained menstruation; 1/2 no longer complained galactorrhea; No change in placebo group

  PMID:23936389 · one of two readings recorded this

• prolactin level normalization rate

  increases, n = 60

  Xu 2006 | Placebo-controlled,single-blind | Female | 6 | 60 | Risperidone Sulpiride | 5 | Aripiprazole: 83.3%Placebo: 0% | 27/28 patients regained menstruation; 16/16 no longer complained galactorrhea; No change in placebo group

  PMID:23936389 · one of two readings recorded this

• regained menstruation among patients with menstrual disturbances

  increases, n = 11

  In one study, 7 of 11 (63.60%) female patients having menstrual disturbances regained menstruation

  PMID:23936389 · one of two readings recorded this

• regained menstruation among patients with menstrual disturbances

  increases, n = 28

  In another study, 27 of 28 (96.43%) patients regained menstruation, and 16 of 16 (100%) patients no longer complained symptom of galactorrhea in aripiprazole group

  PMID:23936389 · one of two readings recorded this

• manic symptoms on the Young Mania Rating Scale (YMRS) at three weeks, aripiprazole vs placebo in acute mania

  decreases, MD -3.66 at three weeks, 95% CI -5.82 to -2.05

  Not recorded as a finding: this platform holds no node for the endpoint

  Evidence shows that aripiprazole was more effective than placebo in reducing manic symptoms in adults and children/adolescents at three and four weeks but not at six weeks (Young Mania Rating Scale (YMRS); mean difference (MD) at three weeks (random effects) -3.66, 95% confidence interval (CI) -5.82 to -2.05; six studies; N = 1819, moderate quality evidence) - a modest difference.

  PMID:24346956 · one of two readings recorded this

• manic symptoms on the Young Mania Rating Scale (YMRS), mean difference at three weeks, aripiprazole versus placebo in acute manic or mixed episodes

  decreases, YMRS MD at three weeks -3.66, 95% CI -5.82 to -2.05 (six studies, N = 1819), n = 1819

  Not recorded as a finding: this platform holds no node for the endpoint

  Evidence shows that aripiprazole was more effective than placebo in reducing manic symptoms in adults and children/adolescents at three and four weeks but not at six weeks (Young Mania Rating Scale (YMRS); mean difference (MD) at three weeks (random effects) -3.66, 95% confidence interval (CI) -5.82 to -2.05; six studies; N = 1819, moderate quality evidence) - a modest difference.

  PMID:24346956 · one of two readings recorded this

• manic symptoms (YMRS), aripiprazole vs other drug treatments

  no effect, n = 972

  YMRS MD at three weeks (random effects) 0.07, 95% CI -1.24 to 1.37; three studies; N = 972

  PMID:24346956 · one of two readings recorded this

• manic symptoms (YMRS), aripiprazole vs placebo

  decreases, n = 1819

  mean difference (MD) at three weeks (random effects) -3.66, 95% confidence interval (CI) -5.82 to -2.05; six studies; N = 1819

  PMID:24346956 · one of two readings recorded this

• participant-reported akathisia, aripiprazole vs lithium

  increases, n = 313

  participant-reported akathisia (RR 2.97, 95% CI 1.37 to 6.43; one study; N = 313)

  PMID:24346956 · one of two readings recorded this

• people requiring anticholinergic medication, aripiprazole vs placebo

  increases, n = 730

  risk ratios (random effects) 3.28, 95% CI 1.82 to 5.91; two studies; N = 730

  PMID:24346956 · one of two readings recorded this

• general extrapyramidal symptoms, aripiprazole vs risperidone

  decreases, n = 2605

  with higher adverse effects seen in participants receiving risperidone of general EPS symptoms (n = 2605, 31 RCTs, RR 0.39 CI 0.31 to 0.50, low quality evidence)

  PMID:24385408 · one of two readings recorded this

• global state, aripiprazole vs olanzapine

  no effect, n = 1739

  there were no significant differences for global state (n = 1739, 11 RCTs, very low quality evidence)

  PMID:24385408 · one of two readings recorded this

• global state, aripiprazole vs quetiapine

  no effect, n = 991

  there were no significant differences for global state (n = 991, 12 RCTs, low quality evidence)

  PMID:24385408 · one of two readings recorded this

• global state, aripiprazole vs risperidone

  no effect, n = 6381

  there were no significant differences for global state (n = 6381, 80 RCTs, low quality evidence)

  PMID:24385408 · one of two readings recorded this

• global state, aripiprazole vs ziprasidone

  no effect, n = 442

  there were no significant differences for global state (n = 442, 6 RCTs, very low quality evidence)

  PMID:24385408 · one of two readings recorded this

• global state (no clinically significant response), aripiprazole vs clozapine

  no effect, n = 2132

  there were no significant differences for global state (no clinically significant response, n = 2132, 29 RCTs, low quality evidence)

  PMID:24385408 · one of two readings recorded this

• leaving the study early for any reason, aripiprazole vs olanzapine

  increases, n = 2331

  Significantly more people receiving aripiprazole left the study early due to any reason (n = 2331, 9 RCTs, RR 1.15 CI 1.05 to 1.25, low quality evidence)

  PMID:24385408 · one of two readings recorded this

• mental state (BPRS), aripiprazole vs clozapine

  no effect, n = 426

  mental state (BPRS, n = 426, 5 RCTs, very low quality evidence)

  PMID:24385408 · one of two readings recorded this

• mental state (BPRS), aripiprazole vs risperidone

  decreases, n = 570

  Data were significantly in favour of aripiprazole for improvement in mental state using the BPRS (n = 570, 5 RCTs, MD 1.33 CI 2.24 to 0.42, very low quality evidence)

  PMID:24385408 · one of two readings recorded this

• quality of life (WHO-QOL-100), aripiprazole vs clozapine

  increases, n = 132

  Quality of life score using the WHO-QOL-100 scale demonstrated significant difference, favouring aripiprazole (n = 132, 2 RCTs, RR 2.59 CI 1.43 to 3.74, very low quality evidence)

  PMID:24385408 · one of two readings recorded this

• quality of life (WHO-QOL-100 total score), aripiprazole vs quetiapine

  increases, n = 100

  Results were significantly in favour of aripiprazole for quality of life (WHO-QOL-100 total score, n = 100, 1 RCT, MD 2.60 CI 1.31 to 3.89, very low quality evidence)

  PMID:24385408 · one of two readings recorded this

• weight gain, aripiprazole vs olanzapine

  decreases, n = 1538

  significantly more people receiving olanzapine gained weight (n = 1538, 9 RCTs, RR 0.25 CI 0.15 to 0.43, very low quality evidence)

  PMID:24385408 · one of two readings recorded this

• weight gain, aripiprazole vs ziprasidone

  increases, n = 232

  Weight gain was significantly greater in people receiving aripiprazole (n = 232, 3 RCTs, RR 4.01 CI 1.10 to 14.60, very low quality evidence)

  PMID:24385408 · one of two readings recorded this

• weight gain, mental state (BPRS, PANSS), global state, extrapyramidal symptoms, quality of life (WHO-QOL-100) and early study leaving with oral aripiprazole compared head-to-head with clozapine, quetiapine, risperidone, ziprasidone and olanzapine in schizophrenia

  increases, weight gain greater with aripiprazole than ziprasidone, RR 4.01 CI 1.10 to 14.60 (n = 232, 3 RCTs), n = 232

  Not recorded as a finding: the comparison was against another active treatment

  Weight gain was significantly greater in people receiving aripiprazole (n = 232, 3 RCTs, RR 4.01 CI 1.10 to 14.60, very low quality evidence).

  PMID:24385408 · one of two readings recorded this

• author-defined tic symptom improvement (rate of progress ≥30 %)

  no effect, p = 0.36, n = 127

  (RR = 1.54, 95 % CI [0.61, 3.88], P = 0.36, I2 = 0)

  PMID:26220447 · one of two readings recorded this

• clinical efficacy rate by CGI Scale, aripiprazole vs haloperidol

  no effect, p = 0.05

  (81.3 % [44/54] vs 82.8 % [39/47], P > 0.05)

  PMID:26220447 · one of two readings recorded this

• impairment score reduction, aripiprazole vs positive controls

  no effect, p = 0.47, n = 255

  (MD = −0.83, 95 % CI [−3.11, 1.44], P = 0.47, I2 = 62 %)

  PMID:26220447 · one of two readings recorded this

• motor tic score reduction (placebo-controlled study)

  no effect, p = 0.05

  no significant difference in reduction of the motor tic score (8.6 ± 6.1 vs 11.9 ± 5.5, P > 0.05)

  PMID:26220447 · one of two readings recorded this

• motor tics score reduction, aripiprazole vs positive controls

  no effect, p = 0.55, n = 411

  the motor tics score (MD = −0.26, 95 % CI [−1.13, 0.60], P = 0.55, I2 = 0)

  PMID:26220447 · one of two readings recorded this

• tic severity on the Yale Global Tic Severity Scale (YGTSS) total score, reduction after 8-12 weeks, aripiprazole versus haloperidol, tiapride, risperidone (11 of 12 studies) or placebo (one study) in children with tic disorders

  total YGTSS after treatment 13.6 ± 9.1 vs 19.9 ± 9.5 aripiprazole vs placebo (single study), P < 0.05

  Not recorded as a finding: this platform holds no node for the endpoint

  One randomized, double-blind, placebo-controlled study used the total YGTSS score as the outcome measurement, and showed a significant difference in reduction of the total YGTSS score (13.6 ± 9.1 vs 19.9 ± 9.5, P < 0.05) and vocal tic score (5.0 ± 4.6 vs 8.0 ± 5.5, P < 0.05) between aripiprazole and placebo.

  PMID:26220447 · one of two readings recorded this

• total tic score reduction, aripiprazole vs positive controls

  no effect, p = 0.93, n = 156

  (MD = −0.2, 95 % CI [−4.47, 4.06], P = 0.93, I2 = 71 %)

  PMID:26220447 · one of two readings recorded this

• total YGTSS score after treatment, single study vs risperidone

  decreases, p = 0.001, n = 60

  (12.8 ± 12 vs 19.3 ± 12.5, P < 0.001)

  PMID:26220447 · one of two readings recorded this

• total YGTSS score reduction, aripiprazole vs haloperidol

  no effect, p = 0.6, n = 285

  (MD = 2.50, 95 % CI [−6.93, 11.92], P = 0.60, I2 = 88 %)

  PMID:26220447 · one of two readings recorded this

• total YGTSS score reduction, aripiprazole vs positive controls pooled

  no effect, p = 0.87, n = 600

  (MD = −0.48, 95 % CI [−6.22, 5.26], P = 0.87, I2 = 87 %)

  PMID:26220447 · one of two readings recorded this

• total YGTSS score reduction, aripiprazole vs risperidone

  unclear, p = 0.04, n = 60

  aripiprazole was not superior to risperidone for improving the YGTSS (MD = −6.50, 95 % CI [−12.71, −0.29], P = 0.04)

  PMID:26220447 · one of two readings recorded this

• total YGTSS score reduction, aripiprazole vs tiapride

  no effect, p = 0.45, n = 255

  (MD = −3.15, 95 % CI [−11.38, 5.09], P = 0.45, I2 = 86 %)

  PMID:26220447 · one of two readings recorded this

• total YGTSS score reduction (placebo-controlled study)

  decreases, p = 0.05

  showed a significant difference in reduction of the total YGTSS score (13.6 ± 9.1 vs 19.9 ± 9.5, P < 0.05)

  PMID:26220447 · one of two readings recorded this

• Tourette Syndrome Global Scale, aripiprazole vs placebo

  decreases, p = 0.02

  (MD = −0.80, 95 % CI [−1.48, −0.12], P = 0.02)

  PMID:26220447 · one of two readings recorded this

• vocal tic score reduction (placebo-controlled study)

  decreases, p = 0.05

  vocal tic score (5.0 ± 4.6 vs 8.0 ± 5.5, P < 0.05)

  PMID:26220447 · one of two readings recorded this

• vocal tics score reduction, aripiprazole vs positive controls

  no effect, p = 0.94, n = 411

  (MD = 0.07, 95 % CI [−1.70, 1.84], P = 0.94, I2 = 74 %)

  PMID:26220447 · one of two readings recorded this

• agitation risk, asenapine vs olanzapine

  increases

  Asenapine had the highest risk of agitation (RR = 1.66)

  PMID:26467415 · one of two readings recorded this

• agitation risk, combined controls

  no effect

  The risk of agitation was not elevated by the newer antipsychotics (RR = 1.07 [0.91-1.28])

  PMID:26467415 · one of two readings recorded this

• agitation risk, newer SGAs vs older SGAs

  increases

  the newer agents did show an increased risk of agitation (RR = 1.34 [1.04-1.71])

  PMID:26467415 · one of two readings recorded this

• akathisia risk, aripiprazole/asenapine/lurasidone combined vs combined controls

  increases, p = 0.00001

  significantly elevated in the combined data from comparative (versus placebo and/or active controls) clinical trials (RR = 2.01 [1.71-2.37], P <0.00001 I2 = 36%)

  PMID:26467415 · one of two readings recorded this

• akathisia risk, aripiprazole vs combined controls

  increases

  Aripiprazole had the lowest risk of the three drugs analyzed but it was still 52% higher than the controls

  PMID:26467415 · one of two readings recorded this

• akathisia risk, aripiprazole vs older SGAs (olanzapine, risperidone, ziprasidone)

  increases

  The risk of akathisia remained elevated (49% higher) with aripiprazole as compared to a combination of older SGAs

  PMID:26467415 · one of two readings recorded this

• akathisia risk, asenapine vs olanzapine

  increases

  Asenapine had the highest risk of akathisia with double the risk of olanzapine (RR = 2.23 [1.45-3.42])

  PMID:26467415 · one of two readings recorded this

• akathisia risk, lurasidone vs combined controls

  increases

  Lurasidone had the highest relative risk at 2.7 [2.02-3.62]; however, this combination of studies was not homogenous (I2 = 64%)

  PMID:26467415 · one of two readings recorded this

• akathisia risk, lurasidone vs placebo

  increases

  Lurasidone had a very high relative risk for akathisia (4.48)

  PMID:26467415 · one of two readings recorded this

• akathisia risk, newer SGAs vs older SGAs

  increases, p = 0.00001

  When compared to older SGAs alone, the risk of akathisia remained elevated for the newer antipsychotics (RR = 1.75 [1.44, 2.14], P <0.00001)

  PMID:26467415 · one of two readings recorded this

• akathisia risk, newer SGAs vs placebo

  increases, p = 0.0001

  When compared to placebos only, the risk of akathisia was high for the newer antipsychotics (RR = 2.55 [1.92-3.39], P<0.0001) but heterogeneity was high (I2=55%)

  PMID:26467415 · one of two readings recorded this

• akathisia risk sensitivity analysis, high-quality studies only

  increases

  Inclusion of only studies of high quality (Jadad score of 4 or 5) increased the risk estimate by 7% (RR = 2.15 versus 2.01)

  PMID:26467415 · one of two readings recorded this

• akathisia risk sensitivity analysis, risperidone or ziprasidone trials eliminated

  increases

  Elimination of risperidone or ziprasidone increased the risk estimate (RR = 2.15 and 2.11 from 2.01, respectively)

  PMID:26467415 · one of two readings recorded this

• akathisia risk sensitivity analysis, trimmed extremes

  increases

  Trimming the ends, or removing the studies reporting the smallest and largest relative risks reduced the risk estimate to 1.94

  PMID:26467415 · one of two readings recorded this

• anxiety risk, lurasidone vs comparators

  increases

  Lurasidone, but not the other drugs or the group, had a significantly higher risk for anxiety versus comparators (RR = 1.36 [1.01-1.85])

  PMID:26467415 · one of two readings recorded this

• anxiety risk, lurasidone vs older SGAs

  unclear

  with lurasidone posing the highest risk (RR = 1.48 [0.99-2.23]

  PMID:26467415 · one of two readings recorded this

• anxiety risk, newer SGAs vs older SGAs

  increases

  The risk of anxiety was also slightly elevated among the newer SGAs as compared to the older ones (RR = 1.19 [1.01-1.41])

  PMID:26467415 · one of two readings recorded this

• dystonia risk, aripiprazole

  unclear

  It is possible that aripiprazole (RR = 0.40[0.12-1.31] reduces the risk of dystonia

  PMID:26467415 · one of two readings recorded this

• dystonia risk, combined controls

  increases

  The newer SGAs had a higher risk of dystonia (combined RR = 1.61 [1.05, 2.48])

  PMID:26467415 · one of two readings recorded this

• dystonia risk, lurasidone

  increases

  Dystonia risk from lurasidone was significantly elevated (RR = 1.81[1.07-3.08])

  PMID:26467415 · one of two readings recorded this

• parkinsonism risk, combined controls

  increases

  Parkinsonism was elevated by the newer antipsychotics (combined RR = 1.61 [1.19-2.17])

  PMID:26467415 · one of two readings recorded this

• suicide or suicidal ideation risk

  no effect, n = 3341

  The risk of suicide or suicide ideation was not significantly elevated among patients taking the newer SGAs (RR = 0.76 [0.37-1.57]

  PMID:26467415 · one of two readings recorded this

• treatment-emergent akathisia incidence, pooled relative risk for aripiprazole, asenapine and lurasidone vs placebo or older second-generation antipsychotics in adults with schizophrenia (BARS and other scales)

  increases, aripiprazole risk 52% higher than controls (placebo and active comparators pooled)

  Not recorded as a finding: this platform holds no node for the endpoint

  Aripiprazole had the lowest risk of the three drugs analyzed but it was still 52% higher than the controls.

  PMID:26467415 · one of two readings recorded this

• treatment-emergent akathisia incidence (relative risk) with aripiprazole versus pooled placebo and older second-generation antipsychotic controls in adults with schizophrenia

  increases, aripiprazole risk of akathisia 52% higher than the controls

  Not recorded as a finding: this platform holds no node for the endpoint

  Aripiprazole had the lowest risk of the three drugs analyzed but it was still 52% higher than the controls.

  PMID:26467415 · one of two readings recorded this

• ABC-Hyperactivity subscale

  decreases, n = 308

  -7.93 points on the ABC - Hyperactivity subscale (95% CI -10.98 to -4.88, two studies, 308 children/adolescents, moderate-quality evidence)

  PMID:27344135 · one of two readings recorded this

• ABC-Irritability subscale

  decreases, n = 308

  Meta-analysis of study results revealed a mean improvement of -6.17 points on the Aberrant Behavior Checklist (ABC) - Irritability subscale (95% confidence intervals (CIs) -9.07 to -3.26, two studies, 308 children/adolescents, moderate-quality evidence)

  PMID:27344135 · one of two readings recorded this

• ABC-Stereotypy subscale

  decreases, n = 308

  -2.66 points on the ABC - Stereotypy subscale (95% CI -3.55 to -1.77, two studies, 308 children/adolescents, moderate-quality evidence)

  PMID:27344135 · one of two readings recorded this

• Relapse of irritability symptoms after randomised discontinuation

  no effect, n = 85

  35% of children/adolescents randomised to continue intervention with aripiprazole relapsed with respect to their symptoms of irritability, compared with 52% of children/adolescents randomised to placebo, for a hazard ratio of 0.57 (95% CI 0.28 to 1.12, 85 children/adolescents, low-quality evidence)

  PMID:27344135 · one of two readings recorded this

• sedation and tremor adverse event risk ratios vs placebo

  increases, sedation RR 4.28, 95% CI 1.58 to 11.60; tremor RR 10.26, 95% CI 1.37 to 76.63

  Not recorded as a finding: no outcome node for sedation or tremor adverse events

  In terms of side effects, children/adolescents taking aripiprazole had a greater increase in weight, with a mean increase of 1.13 kg relative to placebo (95% CI 0.71 to 1.54, two studies, 308 children/adolescents, moderate-quality evidence), and had a higher risk ratio (RR) for sedation (RR 4.28, 95% CI 1.58 to 11.60, two studies, 313 children/adolescents, moderate-quality evidence) and tremor (RR 10.26, 95% CI 1.37 to 76.63, two studies, 313 children/adolescents, moderate-quality evidence).

  PMID:27344135 · one of two readings recorded this

• Sedation

  increases, n = 313

  had a higher risk ratio (RR) for sedation (RR 4.28, 95% CI 1.58 to 11.60, two studies, 313 children/adolescents, moderate-quality evidence)

  PMID:27344135 · one of two readings recorded this

• Tremor

  increases, n = 313

  and tremor (RR 10.26, 95% CI 1.37 to 76.63, two studies, 313 children/adolescents, moderate-quality evidence)

  PMID:27344135 · one of two readings recorded this

• Weight increase

  increases, n = 308

  with a mean increase of 1.13 kg relative to placebo (95% CI 0.71 to 1.54, two studies, 308 children/adolescents, moderate-quality evidence)

  PMID:27344135 · one of two readings recorded this

• Agitation

  no effect, n = 477

  with no significant difference in agitation (2 RCTs, n = 477, RR 0.94, 95% CI 0.80 to 1.11, very low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• At least one adverse effect during the 24 hours after treatment

  no effect, n = 80

  No differences were found in terms of experiencing at least one adverse effect during the 24 hours after treatment (1 RCT, n = 80, RR 0.75, 95% CI 0.45 to 1.24, very low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• At least one adverse effect

  no effect, n = 117

  more people in the aripiprazole compared to the placebo group experienced adverse effects (1 RCT, n = 117, RR 1.51, 95% CI 0.93 to 2.46, very low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• At least one adverse effect

  no effect, n = 113

  Aripiprazole and haloperidol did not differ when taking into account the overall number of people that experienced at least one adverse effect (1 RCT, n = 113, RR 0.91, 95% CI 0.61 to 1.35, very low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• clinically important improvement in agitation at two hours, intramuscular aripiprazole vs placebo in psychosis-induced aggression or agitation, pooled risk ratio

  increases, RR 1.50, 95% CI 1.17 to 1.92

  Not recorded as a finding: this platform holds no node for the endpoint

  Clinically important improvement in agitation at two hours favoured the aripiprazole group (2 RCTs, n = 382, RR 1.50, 95% CI 1.17 to 1.92, very low-quality evidence).

  PMID:29308601 · one of two readings recorded this

• Clinically important improvement in agitation

  increases, n = 382

  Clinically important improvement in agitation at two hours favoured the aripiprazole group (2 RCTs, n = 382, RR 1.50, 95% CI 1.17 to 1.92, very low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• Global state change score

  unclear, n = 80

  had a more favourable effect on global state change scores (1 RCT, n = 80, MD 0.58, 95% CI 0.01 to 1.15, low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• Need for additional injections

  decreases, n = 382

  fewer people in the aripiprazole group needed additional injections compared to the placebo group (2 RCTs, n = 382, RR 0.69, 95% CI 0.56 to 0.85, very low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• Need for additional injections

  increases, n = 477

  Aripiprazole required more injections compared to haloperidol (2 RCTs, n = 477, RR 1.28, 95% CI 1.00 to 1.63, very low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• need for additional intramuscular injections, aripiprazole versus placebo, in people with psychosis-induced aggression or agitation (rapid tranquillisation)

  decreases, RR 0.69, 95% CI 0.56 to 0.85 (2 RCTs, n = 382), n = 382

  Not recorded as a finding: this platform holds no node for the endpoint

  When compared with placebo, fewer people in the aripiprazole group needed additional injections compared to the placebo group (2 RCTs, n = 382, RR 0.69, 95% CI 0.56 to 0.85, very low-quality evidence).

  PMID:29308601 · one of two readings recorded this

• Non-responders after the first injection

  decreases, n = 263

  The numbers of non-responders after the first injection also favoured aripiprazole (1 RCT, n = 263, RR 0.49, 95% CI 0.34 to 0.71, low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• Non-responders after the first injection

  no effect, n = 360

  and similar non-responders after first injection (1 RCT, n = 360, RR 1.18, 95% CI 0.78 to 1.79, low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• Reduction in agitation

  decreases, n = 80

  Compared to aripiprazole, olanzapine was better at reducing agitation (1 RCT, n = 80, RR 0.77, 95% CI 0.60 to 0.99, low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• Somnolence

  decreases, n = 80

  participants allocated to aripiprazole experienced less somnolence (1 RCT, n = 80, RR 0.25, 95% CI 0.08 to 0.82, low-quality evidence)

  PMID:29308601 · one of two readings recorded this

• Constipation

  decreases, p = 0.004

  significantly lower than those with haloperidol for constipation (RR = 0.148; 95% CI: 0.040, 0.553; P =.004)

  PMID:31145316 · one of two readings recorded this

• Dry mouth

  decreases, p = 0.001

  incidence rate of dry mouth between aripiprazole and haloperidol treatment groups (RR = 0.141; 95% CI: 0.046, 0.425; P =.001)

  PMID:31145316 · one of two readings recorded this

• Extrapyramidal symptoms

  decreases

  extrapyramidal symptoms (RR = 0.236; 95% CI: 0. 0.111, 0.505; P =.000)

  PMID:31145316 · one of two readings recorded this

• Incidence of irritability

  increases

  irritability (25%; 95% CI: 9.4%, 66.6%)

  PMID:31145316 · one of two readings recorded this

• Incidence of nausea and vomiting

  increases

  nausea and vomiting (28.9%; 95% CI: 21.1%, 39.5%)

  PMID:31145316 · one of two readings recorded this

• Incidence of restlessness

  increases

  restlessness (31.3%; 95% CI: 13%, 75.1%)

  PMID:31145316 · one of two readings recorded this

• Incidence of sedation

  increases

  sedation (26.9%; 95% CI: 16.3%, 44.4%)

  PMID:31145316 · one of two readings recorded this

• incidence of somnolence adverse events, aripiprazole vs placebo, pooled risk ratio in children and adolescents with tic disorders

  increases, RR 6.565, 95% CI 1.270 to 33.945, p = 0.025

  Not recorded as a finding: this platform holds no node for the endpoint

  The results of meta-analysis showed that there was no significant difference (P >.05) in the incidence rate of AEs between aripiprazole and placebo, except for somnolence (RR = 6.565; 95% CI: 1.270, 33.945; P =.025), as shown in Table 3.

  PMID:31145316 · one of two readings recorded this

• incidence of somnolence as an adverse event, aripiprazole versus placebo in children and adolescents with tic disorders, pooled risk ratio

  increases, RR = 6.565; 95% CI: 1.270, 33.945; P = .025, p = 0.025

  Not recorded as a finding: this platform holds no node for the endpoint

  The results of meta-analysis showed that there was no significant difference (P >.05) in the incidence rate of AEs between aripiprazole and placebo, except for somnolence (RR = 6.565; 95% CI: 1.270, 33.945; P =.025), as shown in Table 3.

  PMID:31145316 · one of two readings recorded this

• Incidence of weight gain

  increases

  weight gain (31.3%; 95% CI: 10.7%, 91.3%)

  PMID:31145316 · one of two readings recorded this

• Nasopharyngitis

  decreases, p = 0.05

  The included studies reported that the occurrence of nasopharyngitis with aripiprazole was significantly lower than that with placebo (P <.05)

  PMID:31145316 · one of two readings recorded this

• Overall incidence of adverse events excluding somnolence

  no effect, n = 194

  The results of meta-analysis showed that there was no significant difference (P >.05) in the incidence rate of AEs between aripiprazole and placebo, except for somnolence

  PMID:31145316 · one of two readings recorded this

• Somnolence

  increases, p = 0.025, n = 194

  except for somnolence (RR = 6.565; 95% CI: 1.270, 33.945; P =.025)

  PMID:31145316 · one of two readings recorded this

• Somnolence

  decreases, p = 0.014

  there was a significant difference between aripiprazole and haloperidol in the rates of somnolence (RR = 0.596; 95% CI: 0.394, 0.901; P =.014)

  PMID:31145316 · one of two readings recorded this

• Tremor

  decreases, p = 0.001

  and tremor (RR = 0.255; 95% CI: 0.114, 0.571; P =.001)

  PMID:31145316 · one of two readings recorded this

• Active moiety concentration in CYP2D6 poor and intermediate metabolizers

  increases

  A Swedish study found an increase in AM concentrations by about 40% in PMs and IMs

  PMID:36195732 · one of two readings recorded this

• Aripiprazole (AM) blood level with carbamazepine co-medication

  decreases

  The mood stabilizers carbamazepine and valproate were found to decrease ARI (AM) BLs by 65% and 23%, respectively

  PMID:36195732 · one of two readings recorded this

• Aripiprazole (AM) blood level with valproate co-medication

  decreases

  The mood stabilizers carbamazepine and valproate were found to decrease ARI (AM) BLs by 65% and 23%, respectively

  PMID:36195732 · one of two readings recorded this

• aripiprazole and dehydro-aripiprazole blood concentration (ng/ml) after oral dosing, pooled mean concentration and concentration-to-dose ratio, and the concentration/efficacy relationship

  combined mean concentration 230 ng/ml [204, 256], n = 3778

  Not recorded as a finding: this platform holds no node for the endpoint

  The combined mean concentration across 17 and nine studies was 230 ng/ml [204, 256] (N = 3778) and 305 [257, 353] (N = 3332, Q = 84.8, df = 9, p < 0.01, I 2 = 98%, T 2 = 5205) for ARI and the AM, respectively (suppl. fig. S 13).

  PMID:36195732 · one of two readings recorded this

• Aripiprazole blood level with CYP3A4 inducers, CYP2D6 inhibitors, alimemazine or lithium

  modulates

  Concurrent treatment with CYP3A4 inducers, CYP2D6 inhibitors, alimemazine, or lithium changed BLs by 40%–60%

  PMID:36195732 · one of two readings recorded this

• Aripiprazole blood level with paroxetine co-medication

  increases

  Two studies showed an increase of ARI BLs after the administration of paroxetine

  PMID:36195732 · one of two readings recorded this

• Concentration-efficacy relationship (CGI), Nemoto et al.

  increases, n = 14

  Nemoto et al. | Prospective CS; paroxetine add-on; fixed ARI doses (mean 14.6 mg); SCZ; N = 14 | Positive (CGI) | Not found (DIEPS) | Yes | Yes | 8/10 | 6/10 | CGI decreased with increasing ARI BL; CAVE: add-on

  PMID:36195732 · one of two readings recorded this

• Concentration-efficacy relationship (PANSS), Lin et al.

  increases, n = 45

  Lin et al. | Prospective CS with flexible doses (mean 15 mg/day); SCZ or SAD; N = 45 | Positive (PANSS) | Not found (AIMS, BARS, SAS) | Yes | No | 6/10 | 4/10 | Higher ARI BL in responders (20% decrease in PANSS score)

  PMID:36195732 · one of two readings recorded this

• Concentration-efficacy relationship (PANSS), Nakamura et al.

  decreases, n = 18

  Nakamura et al. | Prospective CS with fixed doses (mean 22 mg/day); carbamazepine add-on; SCZ; N = 18 | Negative (PANSS) | Positive (UKU) | Yes | Yes | 8/10 | 4/10 | Higher response and less neurological AEs with decreasing ARI BL; CAVE: add-on

  PMID:36195732 · one of two readings recorded this

• Concentration-side effect relationship (BARS akathisia), Hwang et al.

  decreases, n = 79

  Hwang et al. | Cluster RCT with fixed doses (15 mg/day); SCZ or SAD; N = 79 | Not available | Negative (BARS; Akathisia) | No | Yes | 7/10 | Moderate | Higher ARI BL correlated with greater reduction in BARS on day 56

  PMID:36195732 · one of two readings recorded this

• D2/3 receptor occupancy at 15 mg, Kegeles et al.

  n = 19

  Kegeles et al. | CS; N = 19; SCZ or SAD (DSM-4); mean age 29; 79% males | [18F]fallypride | 14 ± 11 (2–40) | NA | D2/3: NA 80 ± 15 (s) in 15 mg | ED80 5.6 ± 1.0 (s) ~ 100 | NA | Dose correlated with ARI BL, PANSS positive scale correlated with D2 occup. (s). No EPS occured.

  PMID:36195732 · one of two readings recorded this

• D2/3 receptor occupancy, Gründer et al.

  Gründer et al. | CS; N = 16/8 (medicated/ medication-free); SCZ or SAD (DSM-4); mean age 30; 94% males | [18F]fallypride | 19 ± 7 (5–30) | 245 ± 307 | D2/3: 83 ± 1 (p), 84 ± 1 (c) | 10 ± 4 (p) 9 ± 4 (c) | 90 (p), 81 (c) | Complete occupancy with ARI BL > 100–150 ng/ml. EC90 for AM is 180 ng/ml.

  PMID:36195732 · one of two readings recorded this

• D2/3 receptor occupancy, Kim et al.

  n = 18

  Kim et al. | RCT; N = 18; healthy volunteers; mean age 23; 100% males | [11C]raclopride | 13 ± 12 (2–30) | Peak: 3.4 ± 0.9 per mg | D2/3: 62 ± 21 (s) | 11.1 (s) | 100 (s) | Values reported for PK model; PK/PD model estimates EC90 of 77 ng/ml (s).

  PMID:36195732 · one of two readings recorded this

• D2/3 receptor occupancy, Takahata et al.

  n = 11

  Takahata et al. | CS; N = 11; healthy volunteers; mean age 24 ± 4; 100% males | [11C]raclopride, [11C]FLB457 | 6 | 29 ± 5 | D2/3: 74 ± 7 (c), 70.1 ± 6.3 (p) | 9.9 (s), 12.2 (p) | 89 (s), 110 (p) | Concentration reported for raclopride scans; lower in FLB457. No preferential extrastriatal binding of ARI.

  PMID:36195732 · one of two readings recorded this

• DDD-corrected mean aripiprazole concentration, men versus women

  increases

  One conflicting result was reported by a study that found 28% higher mean ARI concentrations corrected for defined daily doses (DDD) in men than in woman

  PMID:36195732 · one of two readings recorded this

• Dose-corrected aripiprazole blood level, girls versus boys

  increases

  Linear regression analysis with correction for dose, weight, age, and comedication revealed that girls had about 41% higher BLs than boys

  PMID:36195732 · one of two readings recorded this

• Dose-corrected aripiprazole blood level, women versus men

  increases

  Another study found dose-corrected BLs about 10% higher in women

  PMID:36195732 · one of two readings recorded this

• Dose-corrected aripiprazole concentration, age over 65 years

  increases, n = 1610

  In a large naturalistic dataset (N = 1,610, age 8–92 years), 16% higher dose-corrected concentrations were noted in patients older than 65 years

  PMID:36195732 · one of two readings recorded this

• Dose-corrected aripiprazole concentration in predicted CYP2D6 intermediate metabolizers versus extensive metabolizers

  increases

  Dose-corrected concentrations were 56% higher in predicted PMs, 4% higher in IMs and 11% lower in ultrarapid metabolizers (UMs) compared to EMs

  PMID:36195732 · one of two readings recorded this

• Dose-corrected aripiprazole concentration in predicted CYP2D6 poor metabolizers versus extensive metabolizers

  increases

  Dose-corrected concentrations were 56% higher in predicted PMs, 4% higher in IMs and 11% lower in ultrarapid metabolizers (UMs) compared to EMs

  PMID:36195732 · one of two readings recorded this

• Dose-corrected aripiprazole concentration in predicted CYP2D6 ultrarapid metabolizers versus extensive metabolizers

  decreases

  Dose-corrected concentrations were 56% higher in predicted PMs, 4% higher in IMs and 11% lower in ultrarapid metabolizers (UMs) compared to EMs

  PMID:36195732 · one of two readings recorded this

• Dose versus active moiety (AM) blood concentration (linear regression of study means)

  increases, p = 0.007, n = 3280

  between dose and the AM concentration (N= 3,280, r = 0.79, p = 0.007, suppl. fig. S 12)

  PMID:36195732 · one of two readings recorded this

• Dose versus aripiprazole blood concentration (linear regression of study means)

  increases, p = 0.0001, n = 3778

  show a strong relationship between dose and ARI concentration (N= 3,778, r = 0.85, P < 0.0001, Fig. 2)

  PMID:36195732 · one of two readings recorded this

• Mean aripiprazole blood concentration by dose design

  increases, p = 0.03

  One subgroup comparison “dose design” revealed significantly differing mean drug concentrations between both groups (Chi 2 = 5.0, df = 1, p = 0.03, I 2 = 94%)

  PMID:36195732 · one of two readings recorded this

• Median aripiprazole blood level, CYP2D6 poor versus extensive metabolizers

  increases

  A Norwegian study reported 50% higher median BLs in CYP2D6 poor metabolizers (PM) than in extensive metabolizers (EM)

  PMID:36195732 · one of two readings recorded this

• Akathisia

  increases

  ARI (flexible) | 1.484 (0.162, 13.598) | 0.294 (0.033, 2.578) | 7.608 (2.399, 24.126)

  PMID:38219278 · one of two readings recorded this

• Akathisia

  increases

  ARI | 0.416 (0.104, 1.657) | 5.948 (3.171, 11.158)

  PMID:38219278 · one of two readings recorded this

• Akathisia

  no effect

  ARI3 | 0.365 (0.088, 1.518) | 0.542 (0.049, 6.045) | 0.107 (0.010, 1.150) | 2.778 (0.621, 12.421)

  PMID:38219278 · one of two readings recorded this

• Akathisia

  increases

  BRE | 14.311 (4.177, 49.024)

  PMID:38219278 · one of two readings recorded this

• Akathisia

  no effect

  BRE1 | 0.198 (0.043, 0.921) | 5.127 (0.774, 33.978)

  PMID:38219278 · one of two readings recorded this

• Akathisia

  increases

  BRE2 | 25.914 (4.113, 163.285)

  PMID:38219278 · one of two readings recorded this

• Akathisia

  no effect

  ARI | 0.416 (0.104, 1.657) | 5.948 (3.171, 11.158)

  PMID:38219278 · one of two readings recorded this

• Akathisia

  decreases

  BRE1 | 0.198 (0.043, 0.921) | 5.127 (0.774, 33.978)

  PMID:38219278 · one of two readings recorded this

• Akathisia

  no effect, p = 0.21, n = 447

  Akathisia | 1st week: 0.5 mg/day 2nd week: 1.0 mg/day | 1 | 447 | 2.00 (0.67, 5.95) | 0.21 | NA | p = 0.27, I 2 = 19.0%

  PMID:38219278 · one of two readings recorded this

• Akathisia

  increases, p = 0.01, n = 494

  No titration | 1 | 494 | 5.13 (1.47, 17.94) | 0.01 | NA

  PMID:38219278 · one of two readings recorded this

• Akathisia

  no effect, p = 0.12, n = 773

  Akathisia | 1st week: 0.5 mg/day 2nd week: 1.0 mg/day 3rd week: 2.0 mg/day | 2 | 773 | 3.19 (0.75, 13.47) | 0.12 | 66.0% | p = 0.03, I 2 = 79.5%

  PMID:38219278 · one of two readings recorded this

• Akathisia

  increases, p = 0.00001, n = 490

  1st week: 1 mg/day 2nd week: 2.0 mg/day | 1 | 490 | 25.91 (8.00, 83.93) | <0.00001 | NA

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect

  ARI (flexible) | 1.026 (0.283, 3.718) | 0.419 (0.124, 1.417) | 1.000 (0.491, 2.038)

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect

  ARI | 0.617 (0.185, 2.063) | 1.018 (0.503, 2.060)

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect

  ARI3 | 1.170 (0.464, 2.953) | 1.201 (0.287, 5.030) | 0.491 (0.125, 1.932) | 1.170 (0.453, 3.024)

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect

  BRE | 1.650 (0.619, 4.396)

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect

  BRE1 | 0.409 (0.152, 1.097) | 0.975 (0.333, 2.850)

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect

  BRE2 | 2.384 (0.888, 6.397)

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect

  ARI | 0.617 (0.185, 2.063) | 1.018 (0.503, 2.060)

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect, p = 0.49, n = 447

  All‐cause discontinuation | 1st week: 0.5 mg/day 2nd week: 1.0 mg/day | 1 | 447 | 0.74 (0.32, 1.73) | 0.49 | NA | p = 0.65, I 2 = 0.0%

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect, p = 0.95, n = 494

  No titration | 1 | 494 | 0.97 (0.43, 2.21) | 0.95 | NA

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  no effect, p = 0.26, n = 773

  All‐cause discontinuation | 1st week: 0.5 mg/day 2nd week: 1.0 mg/day 3rd week: 2.0 mg/day | 2 | 773 | 1.67 (0.68, 4.10) | 0.26 | 53.0% | p = 0.54, I 2 = 0.0%

  PMID:38219278 · one of two readings recorded this

• All-cause discontinuation

  increases, p = 0.02, n = 490

  1st week: 1 mg/day 2nd week: 2.0 mg/day | 1 | 490 | 2.38 (1.18, 4.82) | 0.02 | NA

  PMID:38219278 · one of two readings recorded this

• At least one adverse event

  increases

  ARI (flexible) | 1.575 (0.667, 3.718) | 0.904 (0.379, 2.153) | 1.784 (1.071, 2.973)

  PMID:38219278 · one of two readings recorded this

• At least one adverse event

  increases

  ARI | 1.131 (0.652, 1.962) | 1.665 (1.186, 2.339)

  PMID:38219278 · one of two readings recorded this

• At least one adverse event

  no effect

  ARI3 | 0.828 (0.415, 1.653) | 1.304 (0.495, 3.437) | 0.748 (0.282, 1.988) | 1.478 (0.749, 2.916)

  PMID:38219278 · one of two readings recorded this

• At least one adverse event

  no effect

  BRE | 1.472 (0.954, 2.271)

  PMID:38219278 · one of two readings recorded this

• At least one adverse event

  no effect

  BRE1 | 0.574 (0.284, 1.158) | 1.133 (0.568, 2.261)

  PMID:38219278 · one of two readings recorded this

• At least one adverse event

  no effect

  BRE2 | 1.975 (0.979, 3.985)

  PMID:38219278 · one of two readings recorded this

• At least one adverse event

  no effect

  ARI | 1.131 (0.652, 1.962) | 1.665 (1.186, 2.339)

  PMID:38219278 · one of two readings recorded this

• CGI-S

  decreases

  ARI (flexible) | −0.014 (−0.238, 0.212) | 0.114 (−0.112, 0.340) | −0.141 (−0.280, −0.002)

  PMID:38219278 · one of two readings recorded this

• CGI-S

  decreases

  ARI | 0.030 (−0.171, 0.230) | −0.162 (−0.290, −0.033)

  PMID:38219278 · one of two readings recorded this

• CGI-S

  decreases

  ARI3 | −0.072 (−0.257, 0.113) | −0.086 (−0.342, 0.170) | 0.042 (−0.215, 0.299) | −0.213 (−0.399, −0.028)

  PMID:38219278 · one of two readings recorded this

• CGI-S

  decreases

  BRE | −0.191 (−0.345, −0.037)

  PMID:38219278 · one of two readings recorded this

• CGI-S

  decreases

  BRE1 | 0.128 (−0.049, 0.304) | −0.128 (−0.305, 0.050)

  PMID:38219278 · one of two readings recorded this

• CGI-S

  decreases

  BRE2 | −0.255 (−0.433, −0.077)

  PMID:38219278 · one of two readings recorded this

• CGI-S

  no effect

  ARI | 0.030 (−0.171, 0.230) | −0.162 (−0.290, −0.033)

  PMID:38219278 · one of two readings recorded this

• Discontinuation because of adverse events

  no effect

  ARI (flexible) | 2.634 (0.386, 17.997) | 0.405 (0.080, 2.049) | 2.570 (0.900, 7.336)

  PMID:38219278 · one of two readings recorded this

• Discontinuation because of adverse events

  no effect

  ARI | 0.760 (0.155, 3.724) | 2.700 (0.975, 7.478)

  PMID:38219278 · one of two readings recorded this

• Discontinuation because of adverse events

  no effect

  ARI3 | 1.222 (0.450, 3.316) | 3.217 (0.415, 24.923) | 0.495 (0.085, 2.900) | 3.139 (0.887, 11.115)

  PMID:38219278 · one of two readings recorded this

• Discontinuation because of adverse events

  increases

  BRE | 3.552 (1.049, 12.025)

  PMID:38219278 · one of two readings recorded this

• Discontinuation because of adverse events

  no effect

  BRE1 | 0.154 (0.045, 0.529) | 0.976 (0.195, 4.882)

  PMID:38219278 · one of two readings recorded this

• Discontinuation because of adverse events

  increases

  BRE2 | 6.342 (1.843, 21.819)

  PMID:38219278 · one of two readings recorded this

• Discontinuation because of adverse events

  no effect

  ARI | 0.760 (0.155, 3.724) | 2.700 (0.975, 7.478)

  PMID:38219278 · one of two readings recorded this

• Discontinuation because of adverse events

  decreases

  BRE1 | 0.154 (0.045, 0.529) | 0.976 (0.195, 4.882)

  PMID:38219278 · one of two readings recorded this

• Discontinuation due to adverse event

  no effect, p = 0.98, n = 447

  Discontinuation due to adverse event | 1st week: 0.5 mg/day 2nd week: 1.0 mg/day | 1 | 447 | 0.98 (0.20, 4.90) | 0.98 | NA | p = 1.00, I 2 = 0.0%

  PMID:38219278 · one of two readings recorded this

• Discontinuation due to adverse event

  no effect, p = 0.98, n = 494

  No titration | 1 | 494 | 0.98 (0.20, 4.88) | 0.98 | NA

  PMID:38219278 · one of two readings recorded this

• Discontinuation due to adverse event

  increases, p = 0.04, n = 773

  Discontinuation due to adverse event | 1st week: 0.5 mg/day 2nd week: 1.0 mg/day 3rd week: 2.0 mg/day | 2 | 773 | 6.55 (1.14, 37.68) | 0.04 | 0.0% | p = 0.98, I 2 = 0.0%

  PMID:38219278 · one of two readings recorded this

• Discontinuation due to adverse event

  increases, p = 0.003, n = 490

  1st week: 1 mg/day 2nd week: 2.0 mg/day | 1 | 490 | 6.34 (1.84, 21.82) | 0.003 | NA

  PMID:38219278 · one of two readings recorded this

• MADRS

  decreases

  ARI (flexible) | −0.033 (−0.258, 0.193) | −0.074 (−0.299, 0.152) | −0.277 (−0.416, −0.138)

  PMID:38219278 · one of two readings recorded this

• MADRS

  decreases

  ARI | −0.081 (−0.282, 0.120) | −0.305 (−0.434, −0.176)

  PMID:38219278 · one of two readings recorded this

• MADRS

  decreases

  ARI3 | −0.099 (−0.285, 0.086) | −0.132 (−0.389, 0.125) | −0.173 (−0.430, 0.085) | −0.376 (−0.562, −0.190)

  PMID:38219278 · one of two readings recorded this

• MADRS

  decreases

  BRE | −0.224 (−0.378, −0.070)

  PMID:38219278 · one of two readings recorded this

• MADRS

  decreases

  BRE1 | −0.041 (−0.217, 0.136) | −0.244 (−0.422, −0.066)

  PMID:38219278 · one of two readings recorded this

The whole record — 254 rows